RxDoctor Payments Data

Michael Dew, MD

Neurology · Kingsport, TNNPI 1093701427

Payments from drug & device makers

$26,618in general payments, 2019–2025

Across 1,471 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • AbbVie$2K
  • Novartis$2K
  • AstraZeneca$1K
  • Biogen$1K
  • MDD US Operations, LLC$1K
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$390%
  • Food & beverage$26,43799%
  • Education$1411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.131$2,817
AbbVie(2 entities)187$2,150
Novartis84$1,525
AstraZeneca(2 entities)61$1,334
Biogen66$1,248
MDD US Operations, LLC45$1,078
Neurelis, Inc.37$1,034
Lundbeck LLC53$926
Teva Pharmaceuticals USA, Inc.58$846
Neurocrine Biosciences, Inc.42$746
Eisai Inc.38$740
Lilly USA, LLC49$729
Sanofi28$567
Genentech USA, Inc.30$551
Acadia Pharmaceuticals Inc41$549
Amgen27$542
Kyowa Kirin, Inc.23$496
Supernus Pharmaceuticals, Inc.21$455
TG Therapeutics, Inc.19$438
Pfizer30$426
Jazz Pharmaceuticals Inc.18$414
SK Life Science, Inc.19$403
Bristol Myers Squibb23$402
Sunovion Pharmaceuticals Inc.26$400
EMD Serono, Inc.21$382
Johnson & Johnson20$353
Greenwich Biosciences, Inc.15$334
Ipsen Biopharmaceuticals, Inc16$327
Adamas Pharmaceuticals, Inc.14$300
Argenx US, Inc.14$289
Avanir Pharmaceuticals, Inc.16$276
CSL Behring9$246
Otsuka America Pharmaceutical, Inc.13$231
Grifols USA, LLC13$230
Harmony Biosciences LLC10$219
Amneal Pharmaceuticals LLC12$216
Biohaven Pharmaceuticals, Inc.16$206
Biohaven Pharmaceutical Holding Company Ltd.11$180
Corium, LLC8$174
Scilex Pharmaceuticals Inc.8$146
Catalyst Pharmaceuticals, Inc.7$141
Upsher-smith Laboratories LLC8$127
Mallinckrodt Hospital Products Inc.7$121
Sumitomo Pharma America, Inc.10$119
Vanda Pharmaceuticals Inc.5$110
Merz Pharmaceuticals, LLC5$101
Arbor Pharmaceuticals, Inc.5$76
Amylyx Pharmaceuticals, Inc.3$75
E.r. Squibb & Sons, L.L.C.5$73
Livanova USA, Inc.5$68
Axsome Therapeutics, Inc.4$68
GE HealthCare3$57
Impel Pharmaceuticals Inc.2$51
Alnylam Pharmaceuticals Inc.3$50
Zyla Life Sciences, Inc.4$48
Acorda Therapeutics, Inc2$43
Abbott2$33
Boston Scientific2$32
Assertio Therapeutics, Inc.2$32
Medtronic2$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,618 in reported general payments places this provider in the 75th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$88,925
Medicare patients
333
Services billed
728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZeposiaOzanimod Hydrochloride24$220,880
MayzentSiponimod18$190,573
Kesimpta PenOfatumumab13$187,018
Radicava OrsEdaravone13$174,524
Gamunex-CImmune Globul G/Gly/Iga Avg 4617$150,177
Aimovig AutoinjectorErenumab-Aooe168$133,253
IngrezzaValbenazine Tosylate11$88,781
BotoxOnabotulinumtoxina64$79,562
BriviactBrivaracetam40$56,932
GocovriAmantadine Hcl30$52,306
XcopriCenobamate46$51,803
Nurtec OdtRimegepant Sulfate44$45,807
FycompaPerampanel35$45,158
Emgality PenGalcanezumab-Gnlm64$42,941
NourianzIstradefylline20$37,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Zeposia$73$220,88024 claims
NovartisMayzent$1,525$190,57318 claims
Grifols USA, LLCGamunex-C$230$150,17717 claims
AbbVieBotox, Ubrelvy$2,150$99,83783 claims
Neurocrine Biosciences, Inc.Ingrezza$746$88,78111 claims
UCB, Inc.Briviact, Vimpat$2,817$71,89252 claims
MDD US Operations, LLCGocovri$1,078$52,30630 claims
SK Life Science, Inc.Xcopri$403$51,80346 claims
PfizerNurtec Odt$426$45,80744 claims
Eisai Inc.Fycompa$740$45,15835 claims
Kyowa Kirin, Inc.Nourianz$496$37,33720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 361 neurology providers in Tennessee.

Other neurology in Kingsport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →